cubeConsent vs REKOVER

cubeCONSENT supports electronic Informed Consent From (ICF) solution. It provides an optimal learning environment for future subjects and assures that the signing of the subject's consent is based on the patient's accurate understanding on the test and participation in responsibility. cubeCONSENT is interoperated with the cubeCDMS, capturing subjects' informed consent information in real time. cubeCONSENT Key features: - Register a subject in cubeCDMS by signing the consent form - Check the list of subjects registered in the study - Sign the additional consent form for the subject

Welcome To Rekover Study: The REKOVER app is a proprietary platform of ObvioHealth being used to manage a trial to study real-world usage patterns of Skudexa in patients who have been prescribed Skudexa for moderate to severe acute pain. The REKOVER app removes the costly overhead of physical site visits and brings the trial directly to the mobile device of each subject. The result? Robust data collection, increased compliance, faster time to completion, and average cost savings of ~50% vs. traditional on-site trials. Subject Journey A subject who is identified as eligible for this study will be asked by a member of the study team if they would like to participate in the study. If eligible, they will enroll the participant and help them download the REKOVER App. Upon download, the participants create a REKOVER account and complete the Informed Consent process. A series of screens explains the parameters of the study, including: o Privacy Policy o Data Gathering & Usage o Study Tasks & Surveys o Time Commitment o Option to Withdraw Subjects will have the opportunity to connect with a member of the study team to ask questions prior to signing the informed consent form. Intervention Period: Daily Tasks Subjects will contribute data to the study by completing questionnaires over a 5 day period. Subjects can interact with the study team via secure chat.